US FDA grants gunagrabtinib Orphan Drug Designation for the treatment of cholangiocarcinoma

Gunagratinib is a pan-FGFR inhibitor targeting solid tumours with FGFR gene aberrations. According to latest data, 12 patients received treatment and had at least one assessment; overall response rate was 33.3%, including one complete response in a patient with cholangiocarcinoma

Source:

Biospace Inc.